AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
Latest, Q2 2026
33,301
Period ended Jun 30, 2026
Change on a year earlier
+3.3%
32,245 in Q2 2025
History
55 quarters
Since Q4 2012
Sources
54
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accounts payable ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 33,301 | +3.3% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 33,774 | +8.8% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 34,734 | +1,079.4% | Form 10-Q (filed 2026-05-08) ↗ |
| Q3 2025 | Sep 30, 2025 | 33,619 | +10.3% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 32,245 | +9.9% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 31,041 | -0.9% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,945 | -20.1% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 30,492 | +2.8% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 29,329 | +8.5% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 31,326 | +26.4% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,688 | +25.7% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 29,658 | +26.2% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 27,036 | +19.9% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 24,789 | +9.8% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,934 | +1.8% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2022 | Sep 30, 2022 | 23,505 | +7.5% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 22,543 | +8.5% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 22,569 | +9.5% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 2,882 | +26.6% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2021 | Sep 30, 2021 | 21,861 | +12.7% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 20,783 | +7.8% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 20,604 | +62.1% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 2,276 | +56.7% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2020 | Sep 30, 2020 | 19,404 | +58.8% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 19,275 | +70.6% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 12,709 | +7.5% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,452 | -6.1% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 12,217 | +7.5% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 11,300 | +5.7% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 11,826 | +10.8% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,546 | +4.9% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 11,366 | +23.4% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 10,694 | +21.0% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 10,677 | +26.8% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,474 | +4.8% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 9,212 | +1.5% | Form 10-Q (filed 2017-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 8,839 | +1.0% | Form 10-Q (filed 2017-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 8,419 | +2.2% | Form 10-Q (filed 2017-05-05) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,407 | -11.9% | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2016 | Sep 30, 2016 | 9,077 | +12.8% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 8,755 | +20.7% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2016 | Mar 31, 2016 | 8,239 | +27.5% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,597 | +14.0% | Form 10-K (filed 2017-02-17) ↗ |
| Q3 2015 | Sep 30, 2015 | 8,045 | +27.5% | Form 10-Q (filed 2015-11-06) ↗ |
| Q2 2015 | Jun 30, 2015 | 7,251 | +19.9% | Form 10-Q (filed 2015-08-07) ↗ |
| Q1 2015 | Mar 31, 2015 | 6,460 | +4.3% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | 1,401 | +50.2% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2014 | Sep 30, 2014 | 6,312 | -2.0% | Form 10-Q (filed 2014-11-07) ↗ |
| Q2 2014 | Jun 30, 2014 | 6,046 | -5.1% | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 6,196 | -2.1% | Form 10-Q (filed 2014-05-09) ↗ |
| Q4 2013 | Dec 31, 2013 | 933 | +67.8% | Form 10-K (filed 2015-02-20) ↗ |
| Q3 2013 | Sep 30, 2013 | 6,441 | – | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2013 | Jun 30, 2013 | 6,373 | – | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2013 | Mar 31, 2013 | 6,330 | – | Form 10-Q (filed 2013-05-08) ↗ |
| Q4 2012 | Dec 31, 2012 | 556 | – | Form 10-K (filed 2014-02-21) ↗ |
Cite this data
StockData. (2026). AbbVie Accounts payable ($M) ($M), quarterly Q4 2012–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fs_ap
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.